Prelude Therapeutics Inc | Business Contracts

Open Market Sale AgreementSM, dated March 15, 2023, by and between Prelude Therapeutics Incorporated and Jefferies LLC (Filed With SEC on March 15, 2023)

Second Amendment to Single-Tenant Triple Net Lease, dated August 8, 2022, by and between Prelude Therapeutics Incorporated and CRISP Partners LLC (Filed With SEC on November 14, 2022)

Separation Agreement, dated April 6, 2022, between the Registrant and Deborah Morosini, M.D (Filed With SEC on August 9, 2022)

Description of Voting Common Stock Registered Under Section 12 of the Securities Exchange Act of 1943, as amended (Filed With SEC on March 17, 2022)

Second Amended and Restated Entrepreneur Client License Agreement, dated November 1, 2020, by and between Prelude Therapeutics Incorporated and Delaware Innovation Space, Inc (Filed With SEC on November 4, 2020)

Executive Employment Agreement, dated January 21, 2022, by and between the Registrant and Jane Huang (Filed With SEC on May 10, 2022)

First Amendment to Single-Tenant Triple Net Lease, dated November 15, 2021 by and between the Registrant and Crisp Partners, LLC (Filed With SEC on March 17, 2022)

Single-Tenant Triple Net Lease, dated November 30, 2021, by and between the Registrant and Crisp Partners, LLC (Filed With SEC on March 17, 2022)

Executive Employment Agreement, dated December 19, 2020, by and between the Registrant and Brian Piper (Filed With SEC on March 17, 2022)

Executive Employment Agreement, dated November 5, 2021, by and between Registrant and Laurent Chardonnet (Filed With SEC on March 17, 2022)

Executive Employment Agreement, dated December 19, 2020, by and between the Registrant and Andrew Combs (Filed With SEC on March 17, 2022)

Executive Employment Agreement, dated December 19, 2020, by and between the Registrant and Peggy Scherle (Filed With SEC on March 17, 2022)

Description of Voting Common Stock Registered Under Section 12 of the Securities Exchange Act of 1943, as amended (Filed With SEC on March 16, 2021)

Executive Employment Agreement, dated December 19, 2020, by and between the Registrant and Deborah Morosini (Filed With SEC on January 4, 2021)

Executive Employment Agreement, dated December 19, 2020, by and between the Registrant and Christopher Pierce (Filed With SEC on January 4, 2021)

Executive Employment Agreement, dated December 30, 2020, by and between the Registrant and Krishna Vaddi (Filed With SEC on January 4, 2021)

Form of Registration Rights Agreement, by and among the Registrant and certain of its stockholders (Filed With SEC on January 4, 2021)

Form of Underwriting Agreement (Filed With SEC on January 4, 2021)

2020 Employee Stock Purchase Plan, to become effective on the date the registration statement is declared effective, and forms of award agreements (Filed With SEC on September 21, 2020)

2020 Equity Incentive Plan, to become effective on the date immediately prior to the date the registration statement is declared effective, and forms of award agreements (Filed With SEC on September 21, 2020)

Form of Common Stock Certificate (Filed With SEC on September 16, 2020)

Form of Underwriting Agreement (Filed With SEC on September 16, 2020)

Form of Indemnity Agreement (Filed With SEC on September 4, 2020)

Offer Letter, dated April 4, 2019, by and between the Registrant and David Mauro (Filed With SEC on September 4, 2020)

Offer Letter, dated March 21, 2019, by and between the Registrant and Andrew P. Combs (Filed With SEC on September 4, 2020)

Employment Letter, dated October 5, 2017, by and between the Registrant and Krishna Vaddi (Filed With SEC on September 4, 2020)

Amended and Restated Entrepreneur Client License Agreement, dated June 7, 2020, by and between the Registrant and Delaware Innovation Space, Inc (Filed With SEC on September 4, 2020)

2016 Stock Incentive Plan, as amended, and forms of award agreements (Filed With SEC on September 4, 2020)

Amended and Restated Investors Rights Agreement, dated August 21, 2020, by and among the Registrant and certain of its stockholders (Filed With SEC on September 4, 2020)

Prelude Therapeutics Inc (29)